{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:52:26Z","timestamp":1768456346335,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10822-024-00580-2","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T19:15:56Z","timestamp":1731352556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identification of novel inhibitors targeting PI3K\u03b1 via ensemble-based virtual screening method, biological evaluation and molecular dynamics simulation"],"prefix":"10.1007","volume":"38","author":[{"given":"Hui","family":"Zhang","sequence":"first","affiliation":[]},{"given":"Hua-Zhao","family":"Qi","sequence":"additional","affiliation":[]},{"given":"Ya-Juan","family":"Li","sequence":"additional","affiliation":[]},{"given":"Xiu-Yun","family":"Shi","sequence":"additional","affiliation":[]},{"given":"Mei-Ling","family":"Hu","sequence":"additional","affiliation":[]},{"given":"Xiang-Long","family":"Chen","sequence":"additional","affiliation":[]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"issue":"5573","key":"580_CR1","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","volume":"296","author":"LC Cantley","year":"2002","unstructured":"Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296(5573):1655\u20131657. https:\/\/doi.org\/10.1126\/science.296.5573.1655","journal-title":"Science"},{"issue":"7","key":"580_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase\u2013AKT pathway in human cancer. Nat Rev Cancer 2(7):489\u2013501. https:\/\/doi.org\/10.1038\/nrc839","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"580_CR3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","volume":"15","author":"F Janku","year":"2018","unstructured":"Janku F, Yap TA, Meric-Bernstam F (2018) Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol 15(5):273\u2013291. https:\/\/doi.org\/10.1038\/nrclinonc.2018.28","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"580_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.bbapap.2007.10.003","volume":"1784","author":"R Marone","year":"2008","unstructured":"Marone R, Cmiljanovic V, Giese B, Wymann MP (2008) Targeting phosphoinositide 3-kinase\u2014moving towards therapy. Biochim Biophys Acta 1784(1):159\u2013185. https:\/\/doi.org\/10.1016\/j.bbapap.2007.10.003","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"580_CR5","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1158\/2159-8290.CD-18-1175","volume":"9","author":"AB Hanker","year":"2019","unstructured":"Hanker AB, Kaklamani V, Arteaga CL (2019) Challenges for the clinical development of PI3K inhibitors: strategies to improve their impact in solid tumors. Cancer Discov 9(4):482\u2013491. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1175","journal-title":"Cancer Discov"},{"issue":"8","key":"580_CR6","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nrg1879","volume":"7","author":"JA Engelman","year":"2006","unstructured":"Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7(8):606\u2013619. https:\/\/doi.org\/10.1038\/nrg1879","journal-title":"Nat Rev Genet"},{"issue":"2","key":"580_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.tibs.2014.12.003","volume":"40","author":"JE Burke","year":"2015","unstructured":"Burke JE, Williams RL (2015) Synergy in activating class I PI3Ks. Trends Biochem Sci 40(2):88\u2013100. https:\/\/doi.org\/10.1016\/j.tibs.2014.12.003","journal-title":"Trends Biochem Sci"},{"issue":"8","key":"580_CR8","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discovery 8(8):627\u2013644. https:\/\/doi.org\/10.1038\/nrd2926","journal-title":"Nat Rev Drug Discovery"},{"key":"580_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103238","volume":"92","author":"Y Yin","year":"2019","unstructured":"Yin Y, Zhou Y, Sha S, Wu X, Wang SF, Qiao F, Song ZC, Zhu HL (2019) Development of novel chromeno [4, 3-c] pyrazol-4 (2H)-one derivates containing piperazine as inhibitors of PI3K\u03b1. Bioorg Chem 92:103238. https:\/\/doi.org\/10.1016\/j.bioorg.2019.103238","journal-title":"Bioorg Chem"},{"key":"580_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejmech.2017.07.074","volume":"139","author":"YH Fan","year":"2017","unstructured":"Fan YH, Li W, Liu DD, Bai MX, Song HR, Xu YN, Lee SK, Zhou ZP, Wang J (2017) Design, synthesis, and biological evaluation of novel 3-substituted imidazo [1, 2-a] pyridine and quinazolin-4 (3H)-one derivatives as PI3K\u03b1 inhibitors. Eur J Med Chem 139:95\u2013106. https:\/\/doi.org\/10.1016\/j.ejmech.2017.07.074","journal-title":"Eur J Med Chem"},{"issue":"6","key":"580_CR11","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1158\/1078-0432.CCR-11-2123","volume":"18","author":"F Meric-Bernstam","year":"2012","unstructured":"Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Yao J (2012) PIK3CA\/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 18(6):1777\u20131789. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2123","journal-title":"Clin Cancer Res"},{"issue":"1","key":"580_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc3860","volume":"15","author":"LM Thorpe","year":"2015","unstructured":"Thorpe LM, Yuzugullu H, Zhao JJ (2015) PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 15(1):7\u201324. https:\/\/doi.org\/10.1038\/nrc3860","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"580_CR13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550\u2013562. https:\/\/doi.org\/10.1038\/nrc2664","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"580_CR14","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/aps.2015.71","volume":"36","author":"X Wang","year":"2015","unstructured":"Wang X, Ding J, Meng LH (2015) PI3K isoform-selective inhibitors: next-generation targeted cancer therapies. Acta Pharmacol Sin 36(10):1170\u20131176. https:\/\/doi.org\/10.1038\/aps.2015.71","journal-title":"Acta Pharmacol Sin"},{"issue":"10","key":"580_CR15","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.1021\/acs.jmedchem.8b01492","volume":"62","author":"AE Garces","year":"2018","unstructured":"Garces AE, Stocks MJ (2018) Class 1 PI3K clinical candidates and recent inhibitor design strategies: a medicinal chemistry perspective. J Med Chem 62(10):4815\u20134850. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01492","journal-title":"J Med Chem"},{"issue":"3","key":"580_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/biom9030082","volume":"9","author":"MS Miller","year":"2019","unstructured":"Miller MS, Thompson PE, Gabelli SB (2019) Structural determinants of isoform selectivity in PI3K inhibitors. Biomolecules 9(3):82. https:\/\/doi.org\/10.3390\/biom9030082","journal-title":"Biomolecules"},{"issue":"1","key":"580_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.apsb.2016.07.006","volume":"7","author":"W Zhao","year":"2017","unstructured":"Zhao W, QiuY KD (2017) Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy. Acta Pharm Sin B 7(1):27\u201337. https:\/\/doi.org\/10.1016\/j.apsb.2016.07.006","journal-title":"Acta Pharm Sin B"},{"issue":"7","key":"580_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.4155\/fmc.14.28","volume":"6","author":"Y Jeong","year":"2014","unstructured":"Jeong Y, Kwon D, Hong S (2014) Selective and potent small-molecule inhibitors of PI3Ks. Future Med Chem 6(7):737\u2013756. https:\/\/doi.org\/10.4155\/fmc.14.28","journal-title":"Future Med Chem"},{"key":"580_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105900","volume":"173","author":"D Meng","year":"2021","unstructured":"Meng D, He W, Zhang Y, Liang Z, Zheng J, Zhang X, Zhan P, Chen HF, Li WJ, Cai L (2021) Development of PI3K inhibitors: advances in clinical trials and new strategies. Pharmacol Res 173:105900. https:\/\/doi.org\/10.1016\/j.phrs.2021.105900","journal-title":"Pharmacol Res"},{"issue":"2","key":"580_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.annonc.2020.10.596","volume":"32","author":"S Dent","year":"2021","unstructured":"Dent S, Cort\u00e9s J, Im YH, Di\u00e9ras V, Harbeck N, Krop IE, Wilson TR, Cui N, Schimmoller F, Hsu JY, He J, Laurentiis MD, Sousa S, Drullinsky P, Jacot W (2021) Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Ann Oncol 32(2):197\u2013207. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.596","journal-title":"Ann Oncol"},{"issue":"17","key":"580_CR21","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1158\/1078-0432.CCR-16-2888","volume":"23","author":"D Juric","year":"2017","unstructured":"Juric D, De Bono JS, LoRusso PM, Nemunaitis J, Heath EI, Kwak EL, Mercad\u00e9 TM, Geuna E, de Miguel-Luken MJ, Patel C, Kuida K, Sankoh S, Westin EH, Zohren F, Shou Y, Tabernero J (2017) A first-in-human, phase I, dose-escalation study of TAK-117, a selective PI3K\u03b1 isoform inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 23(17):5015\u20135023. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2888","journal-title":"Clin Cancer Res"},{"key":"580_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/1538-7445.10.1158\/1538-7445","volume":"81","author":"M Olivera","year":"2021","unstructured":"Olivera M, Jhaveri K, Juric D, Bedard PL, Cervantes A, Gambardella V, Hamilton E, Italiano A, Kalinsky K, Krop IE, Schmid P, Turner N, Varga A, Lei GY, Royer-Joo S, Thomas P, Schutzman JL, Saura C (2021) Abstract PS11-11: targeted safety events from a phase I\/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET)\u00b1palbociclib (palbo) in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive\/HER2-negative metastatic breast cancer (HR+\/HER2-mBC). Cancer Res 81:11\u201311. https:\/\/doi.org\/10.1158\/1538-7445.10.1158\/1538-7445","journal-title":"Cancer Res"},{"issue":"4","key":"580_CR23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrd3139","volume":"9","author":"G Schneider","year":"2010","unstructured":"Schneider G (2010) Virtual screening: an endless staircase? Nat Rev Drug Discovery 9(4):273\u2013276. https:\/\/doi.org\/10.1038\/nrd3139","journal-title":"Nat Rev Drug Discovery"},{"issue":"8","key":"580_CR24","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1021\/ci300073m","volume":"52","author":"DN Santiago","year":"2012","unstructured":"Santiago DN, Pevzner Y, Durand AA, Tran M, Scheerer RR, Daniel K, Sung S, Woodcock HL, Guida WC, Brooks WH (2012) Virtual target screening: validation using kinase inhibitors. J Chem Inf Model 52(8):2192\u20132203. https:\/\/doi.org\/10.1021\/ci300073m","journal-title":"J Chem Inf Model"},{"key":"580_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.105722","volume":"122","author":"H Zhang","year":"2022","unstructured":"Zhang H, Qi HZ, Mao J, Zhang HR, Luo QQ, Hu ML, Shen C, Ding L (2022) Discovery of novel microtubule stabilizers targeting taxane binding site by applying molecular docking, molecular dynamics simulation, and anticancer activity testing. Bioorg Chem 122:105722. https:\/\/doi.org\/10.1016\/j.bioorg.2022.105722","journal-title":"Bioorg Chem"},{"issue":"1","key":"580_CR26","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1124\/pr.112.007336","volume":"66","author":"G Sliwoski","year":"2014","unstructured":"Sliwoski G, Kothiwale S, Meiler J, Lowe EW (2014) Computational methods in drug discovery. Pharmacol Rev 66(1):334\u2013395. https:\/\/doi.org\/10.1124\/pr.112.007336","journal-title":"Pharmacol Rev"},{"issue":"19","key":"580_CR27","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2174\/1568026619666190816101948","volume":"19","author":"SF da Silva Rocha","year":"2019","unstructured":"da Silva Rocha SF, Olanda CG, Fokoue HH, Sant\u2019Anna CM (2019) Virtual screening techniques in drug discovery: review and recent applications. Curr Top Med Chem 19(19):1751\u20131767. https:\/\/doi.org\/10.2174\/1568026619666190816101948","journal-title":"Curr Top Med Chem"},{"key":"580_CR28","doi-asserted-by":"publisher","unstructured":"Kontoyianni M (2017) Docking and virtual screening in drug discovery. Proteomics Drug Discov. https:\/\/doi.org\/10.1007\/978-1-4939-7201-2_18","DOI":"10.1007\/978-1-4939-7201-2_18"},{"key":"580_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cbpa.2018.06.006","volume":"44","author":"BM Wingert","year":"2018","unstructured":"Wingert BM, Camacho CJ (2018) Improving small molecule virtual screening strategies for the next generation of therapeutics. Curr Opin Chem Biol 44:87\u201392. https:\/\/doi.org\/10.1016\/j.cbpa.2018.06.006","journal-title":"Curr Opin Chem Biol"},{"key":"580_CR30","volume-title":"Bayesian inference in statistical analysis","author":"GE Box","year":"2011","unstructured":"Box GE, Tiao GC (2011) Bayesian inference in statistical analysis. Wiley, New York"},{"key":"580_CR31","volume-title":"Discovery studio 35","author":"AS Inc","year":"2010","unstructured":"Inc AS (2010) Discovery studio 35. Accelrys Software Inc, San Diego"},{"key":"580_CR32","unstructured":"BindingDB Database Home, PI3k\u03b1 non-inhibitors, August 6, 2022. https:\/\/www.bindingdb.org\/rwd\/bind\/index.jsp"},{"issue":"3","key":"580_CR33","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/s0004-3702(98)00016-2","volume":"25","author":"H Zhang","year":"2021","unstructured":"Zhang H, Shen C, Zhang HR, Chen WX, Luo QQ, Ding L (2021) Discovery of novel DGAT1 inhibitors by combination of machine learning methods, pharmacophore model and 3D-QSAR model. Mol Diversity 25(3):1481\u20131495. https:\/\/doi.org\/10.1016\/s0004-3702(98)00016-2","journal-title":"Mol Diversity"},{"key":"580_CR34","volume-title":"Statistical decision theory and Bayesian analysis","author":"JO Berger","year":"2013","unstructured":"Berger JO (2013) Statistical decision theory and Bayesian analysis. Springer, Berlin"},{"issue":"4","key":"580_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1037\/a0016973","volume":"14","author":"C Strobl","year":"2009","unstructured":"Strobl C, Malley J, Tutz G (2009) An introduction to recursive partitioning: rationale, application, and characteristics of classification and regression trees, bagging, and random forests. Psychol Methods 14(4):323. https:\/\/doi.org\/10.1037\/a0016973","journal-title":"Psychol Methods"},{"key":"580_CR36","volume-title":"Statistical learning theory","author":"V Vapnik","year":"1998","unstructured":"Vapnik V (1998) Statistical learning theory. Wiley, New York"},{"key":"580_CR37","doi-asserted-by":"crossref","unstructured":"Keerthi S, Sindhwani V, Chapelle O (2006) An efficient method for gradient-based adaptation of hyperparameters in SVM models. Adv Neural Inf Process Syst 19","DOI":"10.7551\/mitpress\/7503.003.0089"},{"key":"580_CR38","unstructured":"Protein Data Bank (PDB) database, September 20, 2022. https:\/\/www.rcsb.org"},{"issue":"10","key":"580_CR39","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s00894-018-3820-7","volume":"24","author":"SP Kumar","year":"2018","unstructured":"Kumar SP (2018) Receptor pharmacophore ensemble (REPHARMBLE): a probabilistic pharmacophore modeling approach using multiple protein-ligand complexes. J Mol Model 24(10):282. https:\/\/doi.org\/10.1007\/s00894-018-3820-7","journal-title":"J Mol Model"},{"key":"580_CR40","doi-asserted-by":"publisher","unstructured":"Eberhardt J, Santos-Martins D, Tillack AF, Forli S (2021) AutoDock Vina 1.2. 0: new docking methods, expanded force field, and python bindings. J Chem Inf Model 61(8):3891\u20133898. https:\/\/doi.org\/10.1021\/acs.jcim.1c00203","DOI":"10.1021\/acs.jcim.1c00203"},{"issue":"1","key":"580_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/prot.21082","volume":"65","author":"SF Sousa","year":"2006","unstructured":"Sousa SF, Fernandes PA, Ramos MJ (2006) Protein\u2013ligand docking: current status and future challenges. Proteins 65(1):15\u201326. https:\/\/doi.org\/10.1002\/prot.21082","journal-title":"Proteins"},{"issue":"18","key":"580_CR42","doi-asserted-by":"publisher","first-page":"12964","DOI":"10.1039\/c6cp01555g","volume":"18","author":"Z Wang","year":"2016","unstructured":"Wang Z, Sun H, Yao X, Li D, Xu L, Li Y, Tian S, Hou T (2016) Comprehensive evaluation of ten docking programs on a diverse set of protein\u2013ligand complexes: the prediction accuracy of sampling power and scoring power. Phys Chem Chem Phys 18(18):12964\u201312975. https:\/\/doi.org\/10.1039\/c6cp01555g","journal-title":"Phys Chem Chem Phys"},{"issue":"7","key":"580_CR43","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1021\/jm901137j","volume":"53","author":"JB Baell","year":"2010","unstructured":"Baell JB, Holloway GA (2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 53(7):2719\u20132740. https:\/\/doi.org\/10.1021\/jm901137j","journal-title":"J Med Chem"},{"issue":"1","key":"580_CR44","doi-asserted-by":"publisher","first-page":"54127","DOI":"10.1371\/journal.pone.0054127","volume":"8","author":"MI Davis","year":"2013","unstructured":"Davis MI, Sasaki AT, Shen M, Emerling BM, Thorne N, Michael S, Simeonov A (2013) A homogeneous, high-throughput assay for phosphatidylinositol 5-phosphate 4-kinase with a novel, rapid substrate preparation. PLoS ONE 8(1):54127. https:\/\/doi.org\/10.1371\/journal.pone.0054127","journal-title":"PLoS ONE"},{"issue":"16","key":"580_CR45","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D Van Der Spoel","year":"2005","unstructured":"Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ (2005) GROMACS: fast, flexible, and free. J Comput Chem 26(16):1701\u20131718. https:\/\/doi.org\/10.1002\/jcc.20291","journal-title":"J Comput Chem"},{"key":"580_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-0500-5-367","volume":"5","author":"AW Sousa da Silva","year":"2012","unstructured":"Sousa da Silva AW, Vranken WF (2012) ACPYPE-antechamber python parser interface. BMC Res Notes 5:1\u20138. https:\/\/doi.org\/10.1186\/1756-0500-5-367","journal-title":"BMC Res Notes"},{"issue":"8","key":"580_CR47","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.3390\/molecules25081971","volume":"25","author":"G Poli","year":"2020","unstructured":"Poli G, Granchi C, Rizzolio F, Tuccinardi T (2020) Application of MM-PBSA methods in virtual screening. Molecules 25(8):1971. https:\/\/doi.org\/10.3390\/molecules25081971","journal-title":"Molecules"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-024-00580-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-024-00580-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-024-00580-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T12:18:17Z","timestamp":1732623497000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-024-00580-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["580"],"URL":"https:\/\/doi.org\/10.1007\/s10822-024-00580-2","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"37"}}